BRIEF-Veru Reports Positive Results from Phase 2b QUALITY and Maintenance Extension Study

Reuters

06-24

BRIEF-Veru Reports Positive Results from Phase 2b QUALITY and Maintenance Extension Study

June 24 (Reuters) - Veru Inc VERU.O:

VERU REPORTS POSITIVE RESULTS FROM PHASE 2B QUALITY AND MAINTENANCE EXTENSION STUDY SHOWING ENOBOSARM SIGNIFICANTLY REDUCED BODY WEIGHT REGAIN, PREVENTED FAT REGAIN, AND PRESERVED LEAN MASS AFTER SEMAGLUTIDE DISCONTINUATION
VERU INC - ENOBOSARM 3MG REDUCES WEIGHT REGAIN BY 46% AFTER SEMAGLUTIDE DISCONTINUATION
VERU INC - ENOBOSARM SHOWS 93% GREATER FAT LOSS, 100% LEAN MASS PRESERVATION
VERU INC - ENOBOSARM MONOTHERAPY SHOWS POSITIVE SAFETY PROFILE WITH NO GI SIDE EFFECTS
VERU INC - GRANTED FDA MEETING TO DISCUSS PHASE 3 CLINICAL PROGRAM
VERU INC - ENOBOSARM 3MG TO ADVANCE AS PROPOSED DOSE FOR PHASE 3 CLINICAL PROGRAM

Source text: ID:nGNXbbvp7V

Further company coverage: VERU.O

((Reuters.Briefs@thomsonreuters.com;))

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2545287880"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2545287880\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2545287880?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-24 20:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2545287880","market":"nz","top_or_hot":-1,"title":"BRIEF-Veru Reports Positive Results from Phase 2b QUALITY and Maintenance Extension Study","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Veru Reports Positive Results from Phase 2b QUALITY and Maintenance Extension Study </title></head><body><p><span>June 24 (Reuters)</span><span> - </span>Veru Inc <span>VERU.O</span>:</p><ul><li><p>VERU REPORTS POSITIVE RESULTS FROM PHASE 2B QUALITY AND MAINTENANCE EXTENSION STUDY SHOWING ENOBOSARM SIGNIFICANTLY REDUCED BODY WEIGHT REGAIN, PREVENTED FAT REGAIN, AND PRESERVED LEAN MASS AFTER SEMAGLUTIDE DISCONTINUATION</p></li><li><p>VERU INC - ENOBOSARM 3MG REDUCES WEIGHT REGAIN BY 46% AFTER SEMAGLUTIDE DISCONTINUATION</p></li><li><p>VERU INC - ENOBOSARM SHOWS 93% GREATER FAT LOSS, 100% LEAN MASS PRESERVATION</p></li><li><p>VERU INC - ENOBOSARM MONOTHERAPY SHOWS POSITIVE SAFETY PROFILE WITH NO GI SIDE EFFECTS</p></li><li><p>VERU INC - GRANTED FDA MEETING TO DISCUSS PHASE 3 CLINICAL PROGRAM</p></li><li><p>VERU INC - ENOBOSARM 3MG TO ADVANCE AS PROPOSED DOSE FOR PHASE 3 CLINICAL PROGRAM</p></li></ul><p>Source text: <span>ID:nGNXbbvp7V</span></p><p>Further company coverage: <span>VERU.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Veru Reports Positive Results from Phase 2b QUALITY and Maintenance Extension Study</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Veru Reports Positive Results from Phase 2b QUALITY and Maintenance Extension Study\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-06-24 20:36</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Veru Reports Positive Results from Phase 2b QUALITY and Maintenance Extension Study </title></head><body><p><span>June 24 (Reuters)</span><span> - </span>Veru Inc <span>VERU.O</span>:</p><ul><li><p>VERU REPORTS POSITIVE RESULTS FROM PHASE 2B QUALITY AND MAINTENANCE EXTENSION STUDY SHOWING ENOBOSARM SIGNIFICANTLY REDUCED BODY WEIGHT REGAIN, PREVENTED FAT REGAIN, AND PRESERVED LEAN MASS AFTER SEMAGLUTIDE DISCONTINUATION</p></li><li><p>VERU INC - ENOBOSARM 3MG REDUCES WEIGHT REGAIN BY 46% AFTER SEMAGLUTIDE DISCONTINUATION</p></li><li><p>VERU INC - ENOBOSARM SHOWS 93% GREATER FAT LOSS, 100% LEAN MASS PRESERVATION</p></li><li><p>VERU INC - ENOBOSARM MONOTHERAPY SHOWS POSITIVE SAFETY PROFILE WITH NO GI SIDE EFFECTS</p></li><li><p>VERU INC - GRANTED FDA MEETING TO DISCUSS PHASE 3 CLINICAL PROGRAM</p></li><li><p>VERU INC - ENOBOSARM 3MG TO ADVANCE AS PROPOSED DOSE FOR PHASE 3 CLINICAL PROGRAM</p></li></ul><p>Source text: <span>ID:nGNXbbvp7V</span></p><p>Further company coverage: <span>VERU.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"製藥","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250624:nTUABDGWZB:1","article_id":"2545287880","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2545287880","pubTimestamp":1750768565,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Veru Reports Positive Results from Phase 2b QUALITY and Maintenance Extension Study June 24 (Reuters) - Veru Inc VERU.O:VERU REPORTS POSITIVE RESULTS FROM PHASE 2B QUALITY AND MAINTENANCE EXTENS","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","BK4584":"避孕概念","BK4183":"个人用品","BK4557":"大麻股","VERU":"Veru Inc."},"translate_title":"BRIEF-Veru报告2b期质量和维护扩展研究的积极结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VERU":0.9},"content_text":"BRIEF-Veru Reports Positive Results from Phase 2b QUALITY and Maintenance Extension Study June 24 (Reuters) - Veru Inc VERU.O:VERU REPORTS POSITIVE RESULTS FROM PHASE 2B QUALITY AND MAINTENANCE EXTENSION STUDY SHOWING ENOBOSARM SIGNIFICANTLY REDUCED BODY WEIGHT REGAIN, PREVENTED FAT REGAIN, AND PRESERVED LEAN MASS AFTER SEMAGLUTIDE DISCONTINUATIONVERU INC - ENOBOSARM 3MG REDUCES WEIGHT REGAIN BY 46% AFTER SEMAGLUTIDE DISCONTINUATIONVERU INC - ENOBOSARM SHOWS 93% GREATER FAT LOSS, 100% LEAN MASS PRESERVATIONVERU INC - ENOBOSARM MONOTHERAPY SHOWS POSITIVE SAFETY PROFILE WITH NO GI SIDE EFFECTSVERU INC - GRANTED FDA MEETING TO DISCUSS PHASE 3 CLINICAL PROGRAMVERU INC - ENOBOSARM 3MG TO ADVANCE AS PROPOSED DOSE FOR PHASE 3 CLINICAL PROGRAMSource text: ID:nGNXbbvp7VFurther company coverage: VERU.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport,express","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}